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Abstract
Background: The prevalence of vitamin D deficiency in hemodialysis patients is high. While most hemodialysis
patients are treated with activated vitamin D (1,25[OH]2D) to prevent renal osteodystrophy, clinical practices of the
screening and treatment of 25(OH)2D deficiency are highly variable. It is unclear if nutritional vitamin D supplementation
with D2 or D3 provides an additional clinical benefit beyond that provided by activated vitamin D treatment in this
population.
Methods/design: We will conduct a systematic review of nutritional vitamin D (D2/D3) supplementation and
health-related outcomes in hemodialysis patients according to Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) guidelines. The primary objective is to assess the impact of nutritional vitamin D
supplementation on clinical outcomes relevant in hemodialysis patients, such as mortality, cardiovascular events,
infections, and fractures. Secondary outcomes will include anemia, hyperparathyroidism, medication use (erythrocyte-
stimulating agents, activated vitamin D), and quality of life. We will search MEDLINE, Scopus, Web of Science, and
ClinicalTrials.gov for randomized, controlled trials of nutritional vitamin D supplementation (ergocalciferol/D2 or
cholecalciferol/D3) in chronic hemodialysis patients. The Cochrane Risk Assessment Tool will be used to assess
the quality of eligible studies. We will perform meta-analyses using standard techniques for the outcomes listed
above if pooling is deemed appropriate/sufficient. The results of this systematic review may highlight gaps in our
knowledge of the relevance of nutritional vitamin D in end-stage renal disease, allowing for the informed design
of clinical trials assessing the impact of nutritional vitamin D therapy in the hemodialysis population in the future.
Systematic review registration: PROSPERO CRD42014013931
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Background
Over 600,000 individuals live with end-stage renal dis-
ease (ESRD) in the United States [1]. Among ESRD pa-
tients on hemodialysis (HD) as a renal replacement
therapy, cardiovascular disease is the leading cause of
death, and large cohort studies have shown that non-
traditional cardiovascular risk factors, such as vitamin D
deficiency, are associated with increased mortality in this
population [2-8]. Whether or not this risk is mitigated
by treatment of vitamin D deficiency is unknown.
Vitamin D is a steroid hormone, traditionally known
for its role in the regulation of calcium, phosphorus, and
bone metabolism. It can be derived from dietary sources
(D2 and D3) and/or produced in the skin by exposure to
UV light (D3). It is 25-hydroxylated in the liver and then
undergoes 1-alpha-hydroxylation to its active form, 1,25-
dihydroxyvitamin D [1,25(OH)2D], by 1-alpha-hydroxylase
(CYP27B1) in the kidney (in the context of normal renal
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function) as well as in extra-renal sites. 1,25(OH)2D
binds to the intracellular vitamin D receptor (VDR) to
alter gene transcriptional profiles and mediate down-
stream effects [9].
Vitamin D deficiency is widespread among the general
population [10] and is highly prevalent in patients with
ESRD on hemodialysis. The concentration of 25(OH)D
is the main clinical indicator of vitamin D status and is
used to define vitamin D deficiency [11]. According to
the Institute of Medicine (IOM), there is an elevation in
the risk of experiencing adverse health consequences of vita-
min D deficiency at 25(OH)D concentrations <20 ng/mL
[12]. Multiple reports from various centers worldwide
have documented that over 80% of HD patients have
serum vitamin D levels within the insufficient/deficient
range [13,14]. The etiologies of hypovitaminosis D in
the ESRD population are not clear but include limited
sunlight exposure, reduced UVB-induced vitamin D
synthesis in the skin, and disturbed vitamin D metabol-
ism [15-18]. Because renal CYPR27B1 is essentially ab-
sent in patients with ESRD, the levels of circulating
1,25(OH)2D are also commonly well below the normal
range, contributing to secondary hyperparathyroidism
and bone loss. While many of these ESRD patients are
treated with 1,25(OH)2D (or its equivalent) during
hemodialysis for the prevention of uremic bone disease,
this alone may not fully satisfy the vitamin D require-
ment. Increasing experimental evidence indicates that
many vitamin D target tissues, including intestinal and im-
mune cells, express CYP27B1 and the VDR [19-21]. Re-
cent data suggest that local production of 1,25(OH)2D is
required to obtain maximal calcium absorption, expres-
sion of antimicrobial peptides, and anti-inflammatory
effects [19-25]. Because 25(OH)D is the immediate pre-
cursor of 1,25(OH)2D, low serum 25(OH)D concentra-
tions are thus hypothesized to prevent the production
of 1,25(OH)2D in target tissues, potentially promoting
inflammation and reducing other vitamin D effects.
Based on published data demonstrating the prevalence
of vitamin D deficiency in hemodialysis patients and the
possible extra-skeletal benefits of nutritional vitamin D
supplementation, it is imperative to establish recommen-
dations to guide clinical practice and research in this
arena. The purpose of the proposed systematic review is
to provide the best available evidence on the treatment
of vitamin D deficiency in the hemodialysis population
and, if the evidence is inadequate, to highlight areas
where further original research is required.
Methods/design
Research objectives
We will conduct a systematic review to determine the
clinical impact of nutritional vitamin D supplementation
on outcomes in hemodialysis patients (concurrently
treated with 1,25[OH]2D). The pre-specified primary
outcomes will be mortality, cardiovascular events, infec-
tions, and fractures. The secondary outcomes will include
anemia, hyperparathyroidism, medication use (erythro-
cyte-stimulating agents, activated vitamin D), and quality
of life. These pre-defined outcomes may be adjusted dur-
ing the review, depending on the outcomes identified in
eligible studies.
Types of studies
Only randomized, controlled trials (RCTs) of nutritional
vitamin D (D2/ergocalciferol and/or D3/cholecalciferol)
supplementation will be included in this systematic re-
view. The choice to restrict the review to randomized
controlled trials was made to eliminate the bias and con-
founding inherent in observational and uncontrolled
studies of nutritional vitamin D repletion in this popula-
tion. We may, however, find a paucity of eligible studies
using this restriction strategy. If we are unable to find at
least five eligible RCTs for the purposes of this system-
atic review, we will broaden our inclusion criteria (see
below) to include non-randomized and/or uncontrolled
interventional studies of nutritional vitamin D supple-
mentation in HD patients using the Cochrane Effective
Practice and Organization of Care (EPOC) approach to
categorize the types of studies [26].
Search strategy
We will employ a broad electronic search strategy,
using MEDLINE, Scopus, and Web of Science to iden-
tify published abstracts and manuscripts of randomized
controlled trials of nutritional vitamin D supplementa-
tion in hemodialysis patients. To identify unpublished
studies and assess publication bias, we will also search
ClinicalTrials.gov for registered clinical trials of nutri-
tional vitamin D supplementation in hemodialysis pa-
tients. With the goal of prioritizing sensitivity while
remaining specific to clinical trials, the search strategy
will include the relevant key terms: ‘cholecalciferol’ or
‘D3’ or ‘ergocalciferol’ or ‘D2’ and ‘hemodialysis’ and
‘trial’. We will also review the references of included
manuscripts to potentially identify any missed trials.
The corresponding authors of all identified eligible
studies (published and unpublished) will be contacted
to provide de-identified data for the purposes of meta-
analysis.
Study screening and inclusion
All abstracts returned using the search strategy above
will be screened by two independent investigators (WL
and TJ) using the inclusion/exclusion criteria outlined
below. In cases where an abstract is not available, the
full text of the manuscript will be reviewed and evalu-
ated instead. If the two independent investigators
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disagree on whether or not a particular study meets the
inclusion criteria for the review, a third investigator
(AM) will serve as a ‘tiebreaker’. The full text of all stud-
ies deemed eligible for inclusion will then be reviewed
by all investigators for analysis.
Inclusion criteria
We will include all randomized controlled trials of
nutritional vitamin D (D2/ergocalciferol and/or D3/
cholecalciferol) supplementation in adult and pediatric
male and female chronic hemodialysis patients, regardless
of outcome(s) measured. Only randomized, controlled
interventional studies will be included. However, we will
not restrict studies based on outcome(s) assessed, as we
anticipate a limited number of true RCTs. We acknow-
ledge that the type of nutritional supplementation (D2 vs
D3), dose and preparation of supplement(s), and degree of
vitamin D deficiency will vary among studies, but in order
to maximize the total study population, we will not require
any one particular supplement formulation/regimen or
dosing schedule. Studies published in languages other than
English will be translated and included if they otherwise
meet all inclusion/exclusion criteria. As mentioned above,
if we are unable to find at least five eligible RCTs for the
purposes of this systematic review, we will broaden our in-
clusion criteria to include non-randomized and/or uncon-
trolled interventional studies of nutritional vitamin D
supplementation in HD patients.
Exclusion criteria
All case reports/series, review articles, observational
studies, and non-randomized or uncontrolled interven-
tional studies will be excluded. All animal studies will be
excluded. We are also excluding studies of peritoneal
dialysis (PD) and kidney transplant patients as these
ESRD populations do not typically receive intravenous
1,25(OH)2D therapy, an important potential confounder.
Data extraction
Data extraction will be performed in a standardized
fashion for all trials included in the final review using a
pre-formatted database. All extracted data will be veri-
fied by a second investigator to ensure accuracy and
completeness. Study investigator information, study
sites/locations, sample size, inclusion/exclusion criteria,
type and dose of nutritional vitamin D supplements,
follow-up time, and patient characteristics (age, gender,
race, dialysis vintage, comorbidities, dialysis access, med-
ications) will be collected as variables for analysis. Base-
line and follow-up 25(OH)D concentrations will also be
collected, regardless of time of testing. All outcome vari-
ables will also be collected, regardless of number of
studies with that outcome assessed.
Quality assessment
The internal validity of all eligible randomized controlled
trials will be evaluated using the Cochrane Risk Assess-
ment Tool. The tool evaluates studies based on seven
criteria: 1) randomization generation, 2) allocation con-
cealment, 3) blinding of outcome assessors, 4) blinding
patients/study personnel, 5) incomplete outcome data
(that is, lost to follow-up), 6) selective outcome report-
ing, and 7) other risks of bias. Other features to be in-
corporated in the quality assessment include sample size
and statistical analysis (was it appropriate?). In the event
that we include non-randomized and/or uncontrolled
interventional studies of nutritional vitamin D supple-
mentation in HD patients (see ‘Types of studies’ above),
we will use the Cochrane Effective Practice and
Organization of Care Group Draft Risk of Bias Tool to
assess quality and risk of bias [26].
Analysis plan
We will develop a Preferred Reporting Items for System-
atic Reviews and Meta-Analyses (PRISMA) diagram
based on the search strategy and eligibility assessment to
show the flow of included and excluded studies [27]. We
will describe all included studies in detail in the Results
section of the manuscript. Study name/identification, pa-
tient population, and detailed design will be discussed,
with a comparison of outcomes assessed by the various
studies. The descriptive statistics from each trial will also
be included and described in as much detail as is avail-
able from the parent trial(s).
We will pool treatment effect estimates where possible
using standard statistical techniques and RevMan soft-
ware. However, if combining data across studies is not
feasible due to excessive heterogeneity of outcomes, we
will use descriptive methods to present the results of all
eligible studies. We did not specify the duration of ther-
apy in our inclusion criteria in an effort to avoid being
too restrictive, but we will attempt to account for differ-
ences in treatment duration during the data analysis. We
will group both studies of ergocalciferol (D2) and chole-
calciferol (D3) together initially, and we will then per-
form a subsequent sensitivity analysis for each treatment
separately, as the bioavailability of these two agents may
differ [28]. Depending on the heterogeneity of dosing
schedules, we may also perform separate analyses for
differing dosing regimens. Finally, as follow-up time may
vary from trial to trial, we will include time as a covari-
ate in our final data analysis.
Discussion
The National Kidney Foundation (NKF) Kidney Disease
Outcomes Quality Initiative (KDOQI) guidelines do not
address the treatment of vitamin D deficiency in
hemodialysis patients beyond a recommendation for
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treatment with activated vitamin D during hemodialysis
for the prevention of renal osteodystrophy [29]. Perhaps
this is due to a perception that treatment with activated
vitamin D, or 1,25(OH)2D, bypasses any need for its pre-
cursor, 25(OH)D. However, emerging evidence indicates
that vitamin D may play a role in human health that
goes beyond bone and mineral metabolism [11]. As
such, determining the optimal strategy for screening and
repletion of vitamin D deficiency in the ESRD popula-
tion is of vital importance and is the purpose of the pro-
posed systematic review.
We foresee several potential limitations with this sys-
tematic review: heterogeneity of clinical outcomes, sub-
standard quality of existing studies, and a scarcity of
randomized controlled trials, which are the focus of this
project. Therefore, we anticipate that we may have to
broaden our inclusion criteria to include non-randomized/
uncontrolled interventional trials, particularly if we find
fewer than five eligible RCTs for this review. We acknow-
ledge that defining inclusion ‘sufficiency’ as five or more
studies is somewhat arbitrary. However, we wanted to es-
tablish a priori a point at which we will consider changing
our inclusion strategy to maximize the utility of performing
a systematic review on this topic. We also anticipate that
we may not be able to combine eligible studies for a meta-
analysis, but we will nonetheless present our findings using
descriptive methods, if necessary. This study protocol has
been designed prior to any knowledge of the study data or
outcomes from existing published (and non-published) lit-
erature. Hence, we are limited in our capacity to predict
the results. Our hope is that the dissemination of this
protocol will allow us to obtain feedback and constructive
criticism of the methods of our study before it is
conducted.
In conclusion, the proposed systematic review will
provide insight into the clinical impact of nutritional
vitamin D repletion in hemodialysis patients concur-
rently receiving treatment with activated vitamin D. The
results have the potential to inform national and inter-
national guidelines on the care and management of vita-
min D deficiency in this population. The review will also
help to highlight areas requiring further research on this
topic.
Abbreviations
ESRD: end-stage renal disease; HD: hemodialysis; IOM: Institute of Medicine;
KDOQI: Kidney Disease Outcomes Quality Initiative; NKF: National Kidney
Foundation; PRISMA: Preferred Reporting Items for Systematic Reviews and
Meta-Analyses; RCT: randomized controlled trial; VDR: vitamin D receptor.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AM conceived the study, designed the review, and wrote the initial
manuscript. W-YL and TJ performed the initial searches to determine the
feasibility, provided input into the study design, and reviewed the manuscript.
All authors read and approved the final manuscript.
Acknowledgements
AM is supported by UL1TR000067 from the National Center for Advancing
Translational Sciences.
Received: 30 September 2014 Accepted: 19 January 2015
References
1. Collins AJ, Foley RN, Herzog C, Chavers B, Gilbertson D, Herzog C, et al.
US Renal Data System 2012 Annual Data Report. Am J Kidney Dis.
2013;61:A7. e1-476.
2. Brookhart MA, Schneeweiss S, Avorn J, Bradbury BD, Liu J, Winkelmayer WC.
Comparative mortality risk of anemia management practices in incident
hemodialysis patients. JAMA. 2010;303:857–64.
3. Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, et al. Vitamin D
levels and early mortality among incident hemodialysis patients. Kidney Int.
2007;72:1004–13.
4. Servilla KS, Singh AK, Hunt WC, Harford AM, Miskulin D, Meyer KB, et al.
Anemia management and association of race with mortality and
hospitalization in a large not-for-profit dialysis organization. Am J Kidney
Dis. 2009;54:498–510.
5. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact
of anemia on cardiomyopathy, morbidity, and and mortality in end-stage
renal disease. Am J Kidney Dis. 1996;28:53–61.
6. Ofsthun N, Labrecque J, Lacson E, Keen M, Lazarus JM. The effects of higher
hemoglobin levels on mortality and hospitalization in hemodialysis patients.
Kidney Int. 2003;63:1908–14.
7. Gracia-Iguacel C, Gallar P, Qureshi AR, Ortega O, Mon C, Ortiz M, et al.
Vitamin D deficiency in dialysis patients: effect of dialysis modality and
implications on outcome. J Ren Nutr. 2010;20:359–67.
8. Pecovnik-Balon B, Jakopin E, Bevc S, Knehtl M, Gorenjak M. Vitamin D as a
novel nontraditional risk factor for mortality in hemodialysis patients. Ther
Apher Dial. 2009;13:268–72.
9. Bikle D. Nonclassic actions of vitamin D. J Clin Endocrinol Metab.
2009;94:26–34.
10. Looker AC, Johnson CL, Lacher DA, Pfeiffer CM, Schleicher RL, Sempos CT.
Vitamin D status: United States, 2001–2006. NCHS Data Brief. 2011;59:1–8.
11. Holick MF. Vitamin D, deficiency. N Engl J Med. 2007;357:266–81.
12. Pramyothin P, Holick MF. Vitamin D supplementation: guidelines and
evidence for subclinical deficiency. Curr Opin Gastroenterol. 2012;28:139–50.
13. Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, et al. Daily oral
25-hydroxycholecalciferol supplementation for vitamin D deficiency in
haemodialysis patients: effects on mineral metabolism and bone markers.
Nephrol Dial Transplant. 2008;23:3670–6.
14. Sawinski D, Uribarri J, Peace D, Yao T, Wauhop P, Trzcinka P, et al. 25-OH-
vitamin D deficiency and cellular alloimmunity as measured by panel of
reactive T cell testing in dialysis patients. Am J Transplant. 2010;10:2287–95.
15. Mehrotra R, Kermah D, Budoff M, Salusky IB, Mao SS, Gao YL, et al.
Hypovitaminosis D in chronic kidney disease. Clin J Am Soc Nephrol.
2008;3:1144–51.
16. Doorenbos CR, van den Born J, Navis G, de Borst MH. Possible
renoprotection by vitamin D in chronic renal disease: beyond mineral
metabolism. Nat Rev Nephrol. 2009;5:691–700.
17. Jacob AI, Sallman A, Santiz Z, Hollis BW. Defective photoproduction of
cholecalciferol in normal and uremic humans. J Nutr. 1984;114:1313–9.
18. Helvig CF, Cuerrier D, Hosfield CM, Ireland B, Kharebov AZ, Kim JW, et al.
Dysregulation of renal vitamin D metabolism in the uremic rat. Kidney Int.
2010;78:463–72.
19. Lemire JM, Adams JS, Kermani-Arab V, Bakke AC, Sakai R, Jordan SC. 1,25-
Dihydroxyvitamin D3 suppresses human T helper/inducer lymphocyte
activity in vitro. J Immunol. 1985;134:3032–5.
20. Manolagas SC, Provvedini DM, Tsoukas CD. Interactions of 1,25-
dihydroxyvitamin D3 and the immune system. Mol Cell Endocrinol.
1985;43:113–22.
21. Piemonti L, Monti P, Sironi M, Fraticelli P, Leone BE, Dal Cin E, et al. Vitamin
D3 affects differentiation, maturation, and function of human monocyte-derived
dendritic cells. J Immunol. 2000;164:4443–51.
Mehrotra et al. Systematic Reviews Page 4 of 5
22. Chen S, Sims GP, Chen XX, Gu YY, Lipsky PE. Modulatory effects of
1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol.
2007;179:1634–47.
23. Griffin MD, Kumar R. Effects of 1alpha,25(OH)2D3 and its analogs on
dendritic cell function. J Cell Biochem. 2003;88:323–6.
24. Provvedini DM, Tsoukas CD, Deftos LJ, Manolagas SC. 1,25-dihydroxyvitamin
D3 receptors in human leukocytes. Science. 1983;221:1181–3.
25. Provvedini DM, Tsoukas CD, Deftos LJ, Manolagas SC. 1 alpha,25-
Dihydroxyvitamin D3-binding macromolecules in human B lymphocytes:
effects on immunoglobulin production. J Immunol. 1986;136:2734–40.
26. Effective Practice and Organisation of Care (EPOC), EPOC Resources for
review authors. Oslo: Norwegian Knowledge Centre for the Health Services.
http://epocoslo.cochrane.org/epoc-specific-resources-review-authors.
Accessed 14 Jan 2015.
27. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting
items for systematic reviews and meta-analyses: the PRISMA statement. Ann
Intern Med. 2009;151:264–9. W264.
28. Lehmann U, Hirche F, Stangl GI, Hinz K, Westphal S, Dierkes J. Bioavailability
of vitamin D(2) and D(3) in healthy volunteers, a randomized placebo-
controlled trial. J Clin Endocrinol Metab. 2013;98:4339–45.
29. Kramer H, Berns JS, Choi MJ, Martin K, Rocco MV. 25-Hydroxyvitamin D
testing and supplementation in CKD: an NKF-KDOQI controversies report.
Am J Kidney Dis. 2014;64:499–509.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Mehrotra et al. Systematic Reviews Page 5 of 5
